IDH2 and central nervous system cancer: The incidence of an IDH mutation is very high in patients with WHO grade II–III glioma (more than 80%) and secondary glioblastoma (GBM) (73%), while it is uncommon among patients with primary GBM (3.7%) [2,3,4,5].